Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAHERE vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
Treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens (FDA approved indication)
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal half-life approximately 6.2 days (range 3.7-9.5 days) after IV administration; supports every-3-week dosing interval.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
The DM4 component is primarily metabolized by CYP3A4 and, to a lesser extent, by CYP3A5 and CYP2D6. The antibody component undergoes catabolism via proteolytic degradation.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Fecal (approximately 80%) as unchanged drug; renal (approximately 8%) as unchanged drug and metabolites.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 95% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Mean Vd approximately 0.27 L/kg (range 0.14-0.54 L/kg), indicating distribution primarily in plasma and extracellular fluid.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Intravenous only; oral bioavailability not applicable (0% by oral route).
Intravenous administration yields 100% bioavailability.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate to severe hepatic impairment (Child-Pugh B or C).
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established in pediatric patients.
Safety and effectiveness in pediatric patients have not been established.
No specific dose adjustment recommended. Elderly patients (≥65 years) experienced higher rates of serious adverse reactions; monitor closely.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
ELAHERE is not approved for use in patients with platinum-sensitive disease due to increased toxicity and mortality observed in a clinical trial. No other black box warnings.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Ocular toxicity: Corneal toxicity, including keratopathy, blurred vision, dry eyes, and photophobia. Requires ophthalmic monitoring and management with prophylactic corticosteroid eye drops.,Pneumonitis/Interstitial lung disease (ILD): Monitor for cough, dyspnea, or hypoxia; withhold or discontinue if severe.,Peripheral neuropathy: Monitor for sensory or motor neuropathy; dose modify as needed.,Embryo-fetal toxicity: Can cause fetal harm; advise patients of reproductive potential to use effective contraception.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Known severe hypersensitivity to mirvetuximab soravtansine or any of its components,Use in patients with platinum-sensitive disease as safety and efficacy not established and increased risk of serious adverse events
None known.
Avoid grapefruit and grapefruit juice during treatment as they may increase mirvetuximab soravtansine exposure. No other significant food interactions reported.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Based on its mechanism of action (folate receptor alpha-directed antibody-drug conjugate containing maytansinoid DM4, a microtubule inhibitor), ELAHERE is expected to cause embryofetal toxicity and teratogenicity. Malformations and developmental abnormalities are likely if administered during the first trimester. Second and third trimester exposure may result in fetal growth restriction, oligohydramnios, and organ dysfunction due to anti-mitotic effects. There are no adequate human data; animal studies have not been conducted.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., myelosuppression, neurotoxicity) in nursing infants, advise not to breastfeed during treatment and for at least 1 week after the last dose. M/P ratio unknown.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
No recommended dose adjustments in pregnancy due to lack of pharmacokinetic data. Pregnancy is a contraindication due to embryofetal toxicity. If treatment is necessary, exposure-adjusted dosing has not been studied; consider alternative therapies.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate targeting folate receptor alpha (FRα). Administer premedications to reduce infusion reactions. Monitor for ocular toxicity including blurred vision, keratopathy, and dry eye; refer to ophthalmology if symptoms occur. Assess for interstitial lung disease. Use with caution in patients with hepatic impairment due to potential for hepatotoxicity. Contraception required during treatment and for 7 months after last dose.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
This drug targets a protein called folate receptor alpha found on some cancer cells.,You will receive this medication as an intravenous (IV) infusion every 3 weeks.,Common side effects include fatigue, nausea, diarrhea, and blurred vision.,Report any vision changes, shortness of breath, or yellowing of the skin/eyes immediately.,Use effective contraception during treatment and for 7 months after the last dose.,Do not breastfeed during treatment and for 1 month after the last dose.,Stay hydrated and eat small, frequent meals to manage nausea and diarrhea.,Avoid grapefruit and grapefruit juice as it may interact with this medication.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAHERE vs COLUMVI, answered by our medical review team.
ELAHERE is a Antineoplastic Agent that works by ELAHERE (mirvetuximab soravtansine) is an antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα). It consists of a humanized anti-FRα antibody conjugated to the maytansinoid DM4, a microtubule inhibitor. Upon binding to FRα on tumor cells, the ADC is internalized and releases DM4, which binds to tubulin and disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAHERE and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAHERE is: 6 mg/kg adjusted ideal body weight intravenously every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAHERE and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAHERE is classified as Category C. Based on its mechanism of action (folate receptor alpha-directed antibody-drug conjugate containing maytansinoid DM4, a microtubule inhibitor), ELAHERE is expected to cause embryof. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.